

**ASX ANNOUNCEMENT**

21 DECEMBER 2018

RESPIRI LIMITED | \$3.2m SHARE PLACEMENT SETTLEMENT**Issue of Placement Shares**

Further to the ASX announcement by Respiri Limited (ASX: RSH) (the **Company**) of 18 December 2018, the Company can confirm that settlement of the Placement has now occurred and trading of the shares issued under the Placement is expected to occur from 27 December 2018.

CEO Participation in Placement

The Company advises that Executive Director Mario Gattino has committed to invest \$50,000 under the Placement. In accordance with ASX Listing Rule 10.11, the issue of shares to Mario Gattino under the Placement is subject to shareholder approval, which is anticipated to be sought at an extraordinary general meeting of the Company's shareholders in 2019.

Key Placement Details:

Placement Price:	\$0.08 per share
No. of Securities:	39,375,000 fully paid ordinary shares. Additionally, 5,000,000 options to acquire fully paid ordinary shares at an exercise price of \$0.12 per share will be issued to Fawkner Capital Management Pty Ltd (Fawkner Capital) or its nominees. The options will expire on the date that is 24 months from the date of issue of the options, being 21 December 2020. The options will be issued as part of the consideration payable to Fawkner Capital for its role as the Lead Manager of the Placement.
Placement Proceeds:	\$3.2 million (inclusive of CEO participation, subject to shareholder approval)
Lead Manager:	Fawkner Capital

Mario Gattino
CEO

---END---

ABOUT RESPIRI LIMITED

Respiri's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respiri Limited's operations are based in Melbourne, Australia.

FORWARD LOOKING STATEMENTS

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.